Hengrui Pharma Investment Quality Review (600276.SH)

Data timestamp: 2026-08-03 22:13 UTC
Quality score: 64/100
Valuation position: current price/base FV 3.22
Final signal: AVOID

Core Conclusion

Hengrui is an avoid. Current price of CNY53.00 is 3.22x base FV of CNY16.48 and 3.39x conservative FV of CNY15.65. The quality score is below threshold and the valuation embeds a recovery that this report does not underwrite.

Business Breakdown

Five-year revenue CAGR is 9.5%, with latest-year revenue of CNY31.63bn. Innovative pharma optionality is real, but policy pressure, R&D productivity, competition, and evidence uncertainty keep the framework conservative.

Business Quality

The 64/100 score blocks watchlist status. Latest-year FCF was CNY8.27bn. Five-year average ROE was 14.3% and average ROIC was 12.9%. The company has cash resources, but the quality and valuation gates both fail.

Financial Audit

Fiscal 2025 revenue was CNY31.63bn, net profit CNY7.71bn, operating cash flow CNY11.24bn, capex CNY2.96bn, and FCF CNY8.27bn. Five-year FCF/net income was 0.81 and OCF/net income was 1.19. Latest net cash was CNY40.88bn.

Valuation

The conservative case uses CNY8.27bn normalized FCF, 2.0% growth, and 8.0x, producing CNY15.65 per share. The base case uses 4.0% growth and 8.7x, producing CNY16.48. The optimistic case uses 5.0% growth and 12.0x, producing CNY20.59. Current price exceeds all scenarios.

Buy And Tracking Discipline

The action is avoid. Reconsider only if quality score rises above 75, price/base FV falls below 0.70, and evidence improves on R&D return, cash conversion, pricing policy, and capital allocation.

Risk Review

Risks include drug-pricing pressure, R&D failure, product concentration, competition, margin compression, and overpaying for a turnaround. If cash conversion or net cash weakens, the already-low FV should be reduced.

Data Sources

The memo relies on public market and financial data, company filings or investor-relations materials, ChinaBond yield data, and public FX data where applicable. This is research only, not personalized investment advice.